Perrigo Company plc - Form 8-K Summary
Business Context and Reporting Period
Perrigo Company plc, a global pharmaceutical company incorporated in Ireland, filed this Current Report on Form 8-K on August 2, 2024. The filing announces the release of earnings results for the second quarter ended June 29, 2024. The full earnings details are contained in the attached press release (Exhibit 99.1).
Key Financial Metrics
This Form 8-K serves as a notification of the earnings release and does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing text does not provide a clear value for these metrics; they are referenced only as being available in the attached Exhibit 99.1.
Material Changes and Non-GAAP Adjustments
The filing outlines the specific items excluded from the Company's non-GAAP financial measures to facilitate trend analysis. For the three and six months ended June 29, 2024, adjustments include:
- Amortization expense related to acquired intangible assets.
- Restructuring charges and termination benefits.
- Impairment charges.
- Unusual litigation costs.
- Infant formula remediation costs.
- Acquisition and integration-related charges and contingent consideration adjustments.
- Foreign currency translation movements.
Comparative adjustments for the prior year periods (ended July 1, 2023) included milestone payments received related to royalty rights and gains on divestitures, which were not present in the current period's adjustment list.
Guidance, Outlook, and Risks
The filing does not provide specific forward-looking guidance, numerical outlooks, or detailed risk factors. Management commentary is limited to the rationale for using non-GAAP measures, stating they are used for planning, forecasting, and evaluating segment performance. The filing notes that non-GAAP measures should be considered in conjunction with, not in lieu of, GAAP financial statements.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific GAAP and non-GAAP revenue, net income, and earnings per share figures.
- Verify the specific dollar amounts associated with "Infant formula remediation" and "Impairment Charges" impacting the current quarter.
- Confirm the reconciliation between GAAP and non-GAAP net income to understand the magnitude of excluded items.
- Check for any updated full-year guidance provided in the attached press release.